ZA966954B - Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation. - Google Patents

Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.

Info

Publication number
ZA966954B
ZA966954B ZA9606954A ZA966954A ZA966954B ZA 966954 B ZA966954 B ZA 966954B ZA 9606954 A ZA9606954 A ZA 9606954A ZA 966954 A ZA966954 A ZA 966954A ZA 966954 B ZA966954 B ZA 966954B
Authority
ZA
South Africa
Prior art keywords
prevention
polytrauma
blood circulation
extracorporeal blood
selectin antibodies
Prior art date
Application number
ZA9606954A
Other languages
English (en)
Original Assignee
Protein Designs Labs Inc
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Designs Labs Inc, Boehringer Mannheim Gmbh filed Critical Protein Designs Labs Inc
Publication of ZA966954B publication Critical patent/ZA966954B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
ZA9606954A 1995-08-17 1996-08-16 Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation. ZA966954B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95112895 1995-08-17
EP95114696 1995-09-19
US57895395A 1995-12-27 1995-12-27

Publications (1)

Publication Number Publication Date
ZA966954B true ZA966954B (en) 1998-02-16

Family

ID=27236574

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606954A ZA966954B (en) 1995-08-17 1996-08-16 Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.

Country Status (11)

Country Link
EP (1) EP0868197B1 (fr)
JP (1) JP3604699B2 (fr)
AT (1) ATE265861T1 (fr)
AU (1) AU6773596A (fr)
CA (1) CA2229140A1 (fr)
CZ (1) CZ45498A3 (fr)
DE (1) DE69632407T2 (fr)
HU (1) HUP9901673A3 (fr)
PL (1) PL187090B1 (fr)
WO (1) WO1997006822A1 (fr)
ZA (1) ZA966954B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
WO2014143739A2 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anticorps anti-alpha ν bêta 6 et leurs utilisations
WO2014144466A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anticorps anti-alpha ν bêta 6 et leurs utilisations
EP3883635A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie au moyen d'une biothérapie
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232780T2 (de) * 1991-06-25 2003-01-30 Dana-Farber Cancer Institute, Boston Monoklonaler antikörper gegen lymphozytenassoziiertes zelloberflächenprotein
WO1993002698A1 (fr) * 1991-07-29 1993-02-18 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux contre la molecule-1 d'adhesion aux leucocytes
CZ140195A3 (en) * 1992-12-01 1996-06-12 Protein Desing Labs Humanized antibodies reacting with l-selectin
WO1995015181A1 (fr) * 1993-11-30 1995-06-08 Protein Design Labs, Inc. Therapie de reperfusin comprenant l'utilisation d'anticorps diriges contre la l-selectine

Also Published As

Publication number Publication date
EP0868197A4 (fr) 1998-11-18
PL325012A1 (en) 1998-07-06
JPH10510553A (ja) 1998-10-13
DE69632407T2 (de) 2005-06-02
DE69632407D1 (de) 2004-06-09
PL187090B1 (pl) 2004-05-31
HUP9901673A3 (en) 2001-06-28
HUP9901673A2 (hu) 1999-08-30
AU6773596A (en) 1997-03-12
EP0868197B1 (fr) 2004-05-06
JP3604699B2 (ja) 2004-12-22
CA2229140A1 (fr) 1997-02-27
EP0868197A1 (fr) 1998-10-07
WO1997006822A1 (fr) 1997-02-27
CZ45498A3 (cs) 1999-01-13
ATE265861T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
AU594488B2 (en) Agents for the treatment of arthroses
AU3070897A (en) Global financial services integration system and process
NO982310L (no) Protegriner
AU1690497A (en) Automatic well test system and method of operating the same
CA2265464A1 (fr) Traitement pour carence en .alpha.-galactosidase a
AU5794996A (en) Gaming table, tracking system and method
EP0652512A3 (fr) Méthode et système pour la gestion de connexions de composants.
NO890793D0 (no) Fremgangsmaate og installasjon for behandling av vann.
TR199501643A2 (tr) Yünün enzimlerle tedavisi icin yöntem.
NO975557L (no) Immortalisering og dissimortalisering av celler
ZA966954B (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation.
AU7150294A (en) Method and system of collecting, processing and storing blood components
AU7816694A (en) Method and system for the treatment of seeds and bulbs
DE69523296D1 (de) Molkeprotein/polysaccharide Gel, hergestellt durch Hochdruckbehandlung
EP0663218A3 (fr) Méthode et système de stimulation cardiaque en mode VDD(R).
PH30824A (en) Transport of solutions of cellulose through pipes.
DE69625230D1 (de) Thrombininhibitoren
NO974811D0 (no) CNS-utvekstmodulatorer, preparater, celler og fremgangsmåter som omfatter og anvender slike
AU3166295A (en) Imidazopyridine-azolidinones
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
TW336890B (en) Method of making more than one punchout from a single dried blood spot
FI841988A7 (fi) Immunosuppressiivista tekijää tuottava mutantti, humaani T-solulinja sekä menetelmä sellaisten mutanttien tuottamiseksi.
PL319024A1 (en) 4-thia-1-azabicyclo(3.2.0) heptane-3-imino-2-isopropylideno-7-ketoanalgones of beta-lactames, method of obtaining them and their application
TR199700506T1 (xx) Ba��rsak mukozas�ndan tecrit edilen t�m�re- kar��-etkili maddeler, bunlar�n tecrit edilmesi i�in bir y�ntem ve bu maddelerin tatbiki.